Health CareFinancial Results
EBOS Group (ASX: EBO) Targets Higher Cash Flow After $360m Upgrade
EBOS Group lifted FY26 underlying EBITDA by 5% and completed its $360 million distribution upgrade. FY27 capital spending is expected to fall to about $100 million.
EBOEBOS GROUP LIMITEDHealth Care2 min read

EBOS Group has completed its four-year distribution-centre renewal program after investing $360 million across its network. The healthcare and animal-care group expects lower capital spending to support stronger cash generation in FY27.
Revenue rose 9.9% to $13.49 billion in FY26. Underlying EBITDA increased 5% to $614 million, meeting the company’s revised guidance.
However, underlying net profit fell 3.1% to $250 million. Higher depreciation, amortisation and financing costs weighed on earnings after the investment cycle. Statutory net profit increased 4.7% to $225 million.
Revenue Growth Outpaces Profit
EBOS generated a $51 million underlying EBITDA uplift from operating growth. That was partly offset by $22 million of fuel and foreign-exchange headwinds.
The underlying EBITDA margin narrowed to 4.6% from 4.8%. Product mix and competition within community pharmacy contributed to the decline.
Depreciation and amortisation rose by $28 million to $148 million. Net finance costs increased by $13 million to $119 million.
Underlying earnings per share declined 7.3% to 121.7 cents. The final dividend was maintained at NZ61.5 cents per share, producing an 84.5% underlying profit payout ratio.
Healthcare and Animal Care
Healthcare revenue increased 8.5% to $12.58 billion, while underlying EBITDA rose 3.2% to $516 million. Demand for GLP-1 and other high-value medicines supported community pharmacy sales.
Contract logistics gross operating revenue climbed 13.1%. The new Perth facility is now operating, giving EBOS a national Australian healthcare logistics footprint.
Animal Care revenue jumped 34.6% to $907 million. The increase reflected wholesale expansion following the SVS acquisition and continued growth at Lyppard.
Animal Care underlying EBITDA rose 11.6% to $138 million. Branded revenue increased 6.7%, while wholesale revenue advanced 62.2%.
The group deployed $121 million across bolt-on acquisitions during FY26. These transactions expanded its medical technology, retail pharmacy, consumables and animal-care operations.
Cash Flow Reset
Underlying free cash flow fell to $241 million from $302 million. The prior year included a roughly $75 million working-capital benefit linked to the Chemist Warehouse Australia contract exit.
Reported free cash flow was $204 million. Excluding that prior-year benefit, the comparable FY25 figure was $197 million.
Capital expenditure totalled $145 million in FY26. EBOS expects this to fall to about $100 million in FY27 as the distribution investment program ends.
Leverage stood at 2.1 times EBITDA, within the target range of 1.7 to 2.3 times. EBOS also reported about $726 million of undrawn committed bank facilities.
FY27 Guidance
EBOS forecast underlying EBITDA of $635 million to $655 million for FY27. That represents mid-single-digit organic growth at the midpoint of the range.
Depreciation and amortisation are expected between $152 million and $162 million. Net finance costs are forecast at $138 million to $148 million.
The completion of the network program changes the earnings and cash-flow profile. Capital requirements are declining, although prior investment costs will continue flowing through depreciation and interest expenses during FY27.
Latest EBOS GROUP LIMITED ASX Announcements
- 21 Oct 2026 · 2:24 pmMeetings & Governance
- 21 Oct 2026 · 7:53 amPresentations
- 20 Oct 2026 · 9:00 amSecurities Administration
- 20 Oct 2026 · 8:52 amSecurities Administration
- 12 Oct 2026 · 2:36 pmSecurities Administration
- 12 Oct 2026 · 2:35 pmSecurities Administration
- 12 Oct 2026 · 2:22 pmSecurities Administration
- 12 Oct 2026 · 2:19 pmSecurities Administration
![[ASX: LDX] LUMOS DIAGNOSTICS HOLDINGS LIMITED a clinician in an urgent care examination room preparing a fingerstick blood sample beside a compact](/media/hero/14fdc9c1-090a-4cb4-838b-6ccac9e764af/1794196573830-a831dc31-640w.webp)
![[ASX: OCC] ORTHOCELL LIMITED a close-up composition of sustainably sourced pearl shells beside a small sample of processed bone graft biomaterial in](/media/hero/1d78f211-86f4-4939-97eb-81bda5f14669/1793764030563-b679e509-640w.webp)
![[ASX: CC5] CLEVER CULTURE SYSTEMS LIMITED a laboratory scientist loading culture plates into an automated analysis instrument within a clean pharmaceutical quality-control](/media/hero/8a1c5622-2122-437c-ac99-192f57d45b44/1793152635605-44fac865-640w.webp)
![[ASX: FTI] FORTIFAI LTD a close-up of an FPGA circuit board installed within enterprise computing hardware, with connected data cables and rows](/media/hero/8011d2a5-f6a3-4bfe-964e-8ff6969b16e5/1795055492063-6473391f-640w.webp)
![[ASX: EQU] EQUUS ENERGY LIMITED a wide technical cutaway of an offshore gas basin showing established well paths and several adjacent stacked](/media/hero/c3b40ec0-3921-419b-b03f-f771ae196222/1794964746127-937d280b-640w.webp)
![[ASX: NXL] NUIX LIMITED a contemporary software operations centre with analysts reviewing complex data visualisations across multiple monitors, framed in a wide](/media/hero/559b3c82-c553-4948-8adc-e176f2fdc741/1794962185421-3f23d920-640w.webp)